Cargando…

IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours

IDH1 R132H mutation is an important marker of survival in patients with gliomas. Although there are many changes of genes in tumour malignant progression, IDH1 R132H mutation status in glioma progression remained unclear. Here, an in-depth characterization of IDH1 R132H mutations were assessed by im...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Luyan, Xu, Wanzhen, Li, Qingla, Ge, Haitao, Bao, Hongbo, Xia, Songsong, Ji, Jingjing, Jiang, Jie, Song, Yuwen, Gao, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604202/
https://www.ncbi.nlm.nih.gov/pubmed/28928859
http://dx.doi.org/10.7150/jca.20665
_version_ 1783264827780628480
author Mu, Luyan
Xu, Wanzhen
Li, Qingla
Ge, Haitao
Bao, Hongbo
Xia, Songsong
Ji, Jingjing
Jiang, Jie
Song, Yuwen
Gao, Qiang
author_facet Mu, Luyan
Xu, Wanzhen
Li, Qingla
Ge, Haitao
Bao, Hongbo
Xia, Songsong
Ji, Jingjing
Jiang, Jie
Song, Yuwen
Gao, Qiang
author_sort Mu, Luyan
collection PubMed
description IDH1 R132H mutation is an important marker of survival in patients with gliomas. Although there are many changes of genes in tumour malignant progression, IDH1 R132H mutation status in glioma progression remained unclear. Here, an in-depth characterization of IDH1 R132H mutations were assessed by immunohistochemistry in 55 paired primary-recurrent astrocytomas tissues, including 5 paired primary pilocytic astrocytoma (pPA, WHO grade I), 35 paired primary low grade astrocytoma (pLGA, WHO grade II and III) and 15 paired primary high grade astrocytoma (pHGA/ Glioblastoma, WHO grade IV). Meanwhile, the DNA was isolated from paired samples, and PCR amplification was used for IDH1 exon4 sequencing. Nonparametric test, KM and Cox models were used to examine the statistical difference and survival function. We found that the percent of IDH1 R132H mutation was 68.6% (24/35) in pLGA group, but no IDH1 mutation was found in pPA and pHGA groups. Meanwhile, the results from immunohistochemistry and DNA sequencing showed that, compared with primary astrocytoma, there was no change of IDH1 status in recurrent astrocytoma whatever tumour pathological grade raise or indolent. The pPA group has the longest recurrence-free period (RFP) and overall survival (OS) in three groups (p<0.01), while the pHGA group has the shortest ones (p<0.01). In pLGA group, the IDH1 R132H mutation subgroup has longer RFP than IDH1 wild type subgroup (p<0.01), but the OS has no statistical difference between two subgroups (p>0.6). Additionally, IDH1 R132H mutation independently predicted a long RFP in patients with pLGA (HR 1.073, 95% CI 0.151-0.775, p<0.01).
format Online
Article
Text
id pubmed-5604202
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-56042022017-09-19 IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours Mu, Luyan Xu, Wanzhen Li, Qingla Ge, Haitao Bao, Hongbo Xia, Songsong Ji, Jingjing Jiang, Jie Song, Yuwen Gao, Qiang J Cancer Research Paper IDH1 R132H mutation is an important marker of survival in patients with gliomas. Although there are many changes of genes in tumour malignant progression, IDH1 R132H mutation status in glioma progression remained unclear. Here, an in-depth characterization of IDH1 R132H mutations were assessed by immunohistochemistry in 55 paired primary-recurrent astrocytomas tissues, including 5 paired primary pilocytic astrocytoma (pPA, WHO grade I), 35 paired primary low grade astrocytoma (pLGA, WHO grade II and III) and 15 paired primary high grade astrocytoma (pHGA/ Glioblastoma, WHO grade IV). Meanwhile, the DNA was isolated from paired samples, and PCR amplification was used for IDH1 exon4 sequencing. Nonparametric test, KM and Cox models were used to examine the statistical difference and survival function. We found that the percent of IDH1 R132H mutation was 68.6% (24/35) in pLGA group, but no IDH1 mutation was found in pPA and pHGA groups. Meanwhile, the results from immunohistochemistry and DNA sequencing showed that, compared with primary astrocytoma, there was no change of IDH1 status in recurrent astrocytoma whatever tumour pathological grade raise or indolent. The pPA group has the longest recurrence-free period (RFP) and overall survival (OS) in three groups (p<0.01), while the pHGA group has the shortest ones (p<0.01). In pLGA group, the IDH1 R132H mutation subgroup has longer RFP than IDH1 wild type subgroup (p<0.01), but the OS has no statistical difference between two subgroups (p>0.6). Additionally, IDH1 R132H mutation independently predicted a long RFP in patients with pLGA (HR 1.073, 95% CI 0.151-0.775, p<0.01). Ivyspring International Publisher 2017-08-22 /pmc/articles/PMC5604202/ /pubmed/28928859 http://dx.doi.org/10.7150/jca.20665 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Mu, Luyan
Xu, Wanzhen
Li, Qingla
Ge, Haitao
Bao, Hongbo
Xia, Songsong
Ji, Jingjing
Jiang, Jie
Song, Yuwen
Gao, Qiang
IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours
title IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours
title_full IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours
title_fullStr IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours
title_full_unstemmed IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours
title_short IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours
title_sort idh1 r132h mutation is accompanied with malignant progression of paired primary-recurrent astrocytic tumours
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604202/
https://www.ncbi.nlm.nih.gov/pubmed/28928859
http://dx.doi.org/10.7150/jca.20665
work_keys_str_mv AT muluyan idh1r132hmutationisaccompaniedwithmalignantprogressionofpairedprimaryrecurrentastrocytictumours
AT xuwanzhen idh1r132hmutationisaccompaniedwithmalignantprogressionofpairedprimaryrecurrentastrocytictumours
AT liqingla idh1r132hmutationisaccompaniedwithmalignantprogressionofpairedprimaryrecurrentastrocytictumours
AT gehaitao idh1r132hmutationisaccompaniedwithmalignantprogressionofpairedprimaryrecurrentastrocytictumours
AT baohongbo idh1r132hmutationisaccompaniedwithmalignantprogressionofpairedprimaryrecurrentastrocytictumours
AT xiasongsong idh1r132hmutationisaccompaniedwithmalignantprogressionofpairedprimaryrecurrentastrocytictumours
AT jijingjing idh1r132hmutationisaccompaniedwithmalignantprogressionofpairedprimaryrecurrentastrocytictumours
AT jiangjie idh1r132hmutationisaccompaniedwithmalignantprogressionofpairedprimaryrecurrentastrocytictumours
AT songyuwen idh1r132hmutationisaccompaniedwithmalignantprogressionofpairedprimaryrecurrentastrocytictumours
AT gaoqiang idh1r132hmutationisaccompaniedwithmalignantprogressionofpairedprimaryrecurrentastrocytictumours